Chronic Obstructive Pulmonary Disease | Decision Base | US | 2015
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market?
Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients’ COPD worsens. Although substantial opportunity exists for a disease-modifying therapy, development of new COPD therapies has focused instead on therapies that combine two bronchodilators in one inhaler. As the COPD marketplace becomes increasingly crowded with these fixed-dose combinations, emerging therapies will need to be clearly differentiated from competitors to experience substantial uptake.
Related Market Assessment Reports
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
